Masimo vs Integer: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Masimo Corporation (MASI)

Q3 202622 Jun – 22 Jul 2026

▲3

Masimo acquired by Danaher; FDA win and Apple patent ruling shape outlook

Danaher completes $9.9B acquisition of Masimo Danaher finished buying Masimo for $9.9 billion, and Masimo's stock was delisted from NASDAQ. Shareholders got a premium. Masimo now runs as a standalone unit inside Danaher's diagnostics business, so MASI no longer trades as a separate public stock.
This is the single biggest event that changes MASI's status and price permanently.
FDA clears AI opioid detection on Radius VSM Masimo won FDA clearance for an AI feature that detects opioid-related breathing problems on its wearable monitor. This expands Masimo's product usefulness in hospitals and could drive more sales of its monitoring systems, supporting the value Danaher paid.
New product approval directly boosts Masimo's growth potential and justifies the acquisition.
Apple patent verdict upheld, but trade secret damages denied A judge kept a $634 million patent win for Masimo against Apple, but rejected Masimo's claim for up to $3.1 billion in trade secret damages. Masimo is appealing. The mixed outcome leaves legal uncertainty but preserves a major cash award.
This legal battle affects Masimo's finances and future royalty income, a key swing factor.
Danaher Q2 results show Masimo integration on track Danaher's second-quarter results were solid, with Masimo contributing and helping offset higher debt costs from the acquisition. This suggests Masimo's business is performing as expected inside Danaher, supporting the deal's long-term value.
Confirms the acquisition is adding value and not dragging on Danaher, which matters for Masimo's future funding and growth.

July 202622 Jun – 22 Jul 2026

▲3

Masimo acquired by Danaher; FDA win and Apple patent ruling shape outlook

Danaher completes $9.9B acquisition of Masimo Danaher finished buying Masimo for $9.9 billion, and Masimo's stock was delisted from NASDAQ. Shareholders got a premium. Masimo now runs as a standalone unit inside Danaher's diagnostics business, so MASI no longer trades as a separate public stock.
This is the single biggest event that changes MASI's status and price permanently.
FDA clears AI opioid detection on Radius VSM Masimo won FDA clearance for an AI feature that detects opioid-related breathing problems on its wearable monitor. This expands Masimo's product usefulness in hospitals and could drive more sales of its monitoring systems, supporting the value Danaher paid.
New product approval directly boosts Masimo's growth potential and justifies the acquisition.
Apple patent verdict upheld, but trade secret damages denied A judge kept a $634 million patent win for Masimo against Apple, but rejected Masimo's claim for up to $3.1 billion in trade secret damages. Masimo is appealing. The mixed outcome leaves legal uncertainty but preserves a major cash award.
This legal battle affects Masimo's finances and future royalty income, a key swing factor.
Danaher Q2 results show Masimo integration on track Danaher's second-quarter results were solid, with Masimo contributing and helping offset higher debt costs from the acquisition. This suggests Masimo's business is performing as expected inside Danaher, supporting the deal's long-term value.
Confirms the acquisition is adding value and not dragging on Danaher, which matters for Masimo's future funding and growth.

Latest22 Jun – 22 Jul 2026

▲3

Masimo acquired by Danaher; FDA win and Apple patent ruling shape outlook

Danaher completes $9.9B acquisition of Masimo Danaher finished buying Masimo for $9.9 billion, and Masimo's stock was delisted from NASDAQ. Shareholders got a premium. Masimo now runs as a standalone unit inside Danaher's diagnostics business, so MASI no longer trades as a separate public stock.
This is the single biggest event that changes MASI's status and price permanently.
FDA clears AI opioid detection on Radius VSM Masimo won FDA clearance for an AI feature that detects opioid-related breathing problems on its wearable monitor. This expands Masimo's product usefulness in hospitals and could drive more sales of its monitoring systems, supporting the value Danaher paid.
New product approval directly boosts Masimo's growth potential and justifies the acquisition.
Apple patent verdict upheld, but trade secret damages denied A judge kept a $634 million patent win for Masimo against Apple, but rejected Masimo's claim for up to $3.1 billion in trade secret damages. Masimo is appealing. The mixed outcome leaves legal uncertainty but preserves a major cash award.
This legal battle affects Masimo's finances and future royalty income, a key swing factor.
Danaher Q2 results show Masimo integration on track Danaher's second-quarter results were solid, with Masimo contributing and helping offset higher debt costs from the acquisition. This suggests Masimo's business is performing as expected inside Danaher, supporting the deal's long-term value.
Confirms the acquisition is adding value and not dragging on Danaher, which matters for Masimo's future funding and growth.

Integer Holdings Corp (ITGR)

Q3 202617 Jul – 6 Aug 2026

▲2▼1

KKR's $127-a-share buyout deal is now the whole story for ITGR

KKR agrees to buy Integer for $127 a share KKR signed a definitive deal to take Integer private for $127 a share in cash, about $5.7 billion, a 51.8% premium to the price before the strategic review. The stock jumped toward the offer, and the deal is expected to close by year-end.
This is the single new event that now sets ITGR's price, so it is the core answer.
No financing risk, but a vote and regulators must clear it The buyer needs no financing, so the main risks are stockholders approving the deal and regulators clearing it. If it closes, Integer leaves the New York Stock Exchange and becomes privately held, so the shares stop trading publicly.
Explains the real conditions and counterweight behind the agreed deal, which readers need to judge it.
Analysts cut ratings; fair-value estimates still sit below the offer After the deal, analysts downgraded the stock to neutral, saying further gains depend on the deal closing. One fair-value estimate rose to $112.14, still under the $127 offer, while another model says $139. This shows the price is now pinned near the deal terms, not company performance.
Gives the honest counterweight: upside is limited and tied to completion, not to the business.
Insurance-driven procedure slowdown is now a side issue An Intuitive Surgical warning that insurance changes could slow U.S. procedures briefly dragged medical device stocks down, including Integer. With the buyout agreed, this demand worry matters far less to the price than the deal itself.
It is the only negative force this period, but the buyout has largely overtaken it.

July 202617 Jul – 6 Aug 2026

▲2▼1

KKR's $127-a-share buyout deal is now the whole story for ITGR

KKR agrees to buy Integer for $127 a share KKR signed a definitive deal to take Integer private for $127 a share in cash, about $5.7 billion, a 51.8% premium to the price before the strategic review. The stock jumped toward the offer, and the deal is expected to close by year-end.
This is the single new event that now sets ITGR's price, so it is the core answer.
No financing risk, but a vote and regulators must clear it The buyer needs no financing, so the main risks are stockholders approving the deal and regulators clearing it. If it closes, Integer leaves the New York Stock Exchange and becomes privately held, so the shares stop trading publicly.
Explains the real conditions and counterweight behind the agreed deal, which readers need to judge it.
Analysts cut ratings; fair-value estimates still sit below the offer After the deal, analysts downgraded the stock to neutral, saying further gains depend on the deal closing. One fair-value estimate rose to $112.14, still under the $127 offer, while another model says $139. This shows the price is now pinned near the deal terms, not company performance.
Gives the honest counterweight: upside is limited and tied to completion, not to the business.
Insurance-driven procedure slowdown is now a side issue An Intuitive Surgical warning that insurance changes could slow U.S. procedures briefly dragged medical device stocks down, including Integer. With the buyout agreed, this demand worry matters far less to the price than the deal itself.
It is the only negative force this period, but the buyout has largely overtaken it.

Latest17 Jul – 6 Aug 2026

▲2▼1

KKR's $127-a-share buyout deal is now the whole story for ITGR

KKR agrees to buy Integer for $127 a share KKR signed a definitive deal to take Integer private for $127 a share in cash, about $5.7 billion, a 51.8% premium to the price before the strategic review. The stock jumped toward the offer, and the deal is expected to close by year-end.
This is the single new event that now sets ITGR's price, so it is the core answer.
No financing risk, but a vote and regulators must clear it The buyer needs no financing, so the main risks are stockholders approving the deal and regulators clearing it. If it closes, Integer leaves the New York Stock Exchange and becomes privately held, so the shares stop trading publicly.
Explains the real conditions and counterweight behind the agreed deal, which readers need to judge it.
Analysts cut ratings; fair-value estimates still sit below the offer After the deal, analysts downgraded the stock to neutral, saying further gains depend on the deal closing. One fair-value estimate rose to $112.14, still under the $127 offer, while another model says $139. This shows the price is now pinned near the deal terms, not company performance.
Gives the honest counterweight: upside is limited and tied to completion, not to the business.
Insurance-driven procedure slowdown is now a side issue An Intuitive Surgical warning that insurance changes could slow U.S. procedures briefly dragged medical device stocks down, including Integer. With the buyout agreed, this demand worry matters far less to the price than the deal itself.
It is the only negative force this period, but the buyout has largely overtaken it.